ICMJE DISCLOSURE FORM

Date: March 25, 2023 Your Name: Arian Lasocki

Manuscript Title: Radiogenomics of adult intracranial gliomas after the 2021 World Health Organisation

classification: a review of changes, challenges and opportunities

Manuscript number (if known): QIMS-22-1365

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
	li	me frame: Since the initia	l planning of the work
1	All support for the	XNone	
	present manuscript (e.g.,		
	funding, provision of study materials, medical		
	writing, article processing		
	charges, etc.)		
	No time limit for this		
	item.		
		T: f	00
		Time frame: past	36 months
2	Grants or contracts from	X_None	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	X_None	

4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued	X None
	or pending	
9	Participation on a Data	X None
	Safety Monitoring Board	
	or Advisory Board	
10	Leadership or fiduciary	X None
	role in other board,	
	society, committee or	
	advocacy group, paid or	
	unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non- financial interests	X_None
Plea	se summarize the above	e conflict of interest in the following box:
No	one.	
1		
Plea	se place an "X" next to t	the following statement to indicate your agreement:
	-	- · · · · · · · · · · · · · · · · · · ·

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: March 25, 2023

Your Name: Samuel Roberts-Thomson

Manuscript Title: Radiogenomics of adult intracranial gliomas after the 2021 World Health Organisation

classification: a review of changes, challenges and opportunities

Manuscript number (if known): QIMS-22-1365

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Ti	Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work
_	All a second feedbar	V. N.	
1	All support for the	X_None	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this		
	item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued	X None
	or pending	
9	Participation on a Data	X None
	Safety Monitoring Board	
	or Advisory Board	
10	Leadership or fiduciary	X None
	role in other board,	
	society, committee or	
	advocacy group, paid or	
	unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non- financial interests	X_None
Plea	se summarize the above	e conflict of interest in the following box:
No	one.	
1		
Plea	se place an "X" next to t	the following statement to indicate your agreement:
	-	- · · · · · · · · · · · · · · · · · · ·

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.

ICMJE DISCLOSURE FORM

Date: March 25, 2023 Your Name: Frank Gaillard

Manuscript Title: Radiogenomics of adult intracranial gliomas after the 2021 World Health Organisation

classification: a review of changes, challenges and opportunities

Manuscript number (if known): QIMS-22-1365

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Ti	Name all entities with whom you have this relationship or indicate none (add rows as needed) me frame: Since the initia	Specifications/Comments (e.g., if payments were made to you or to your institution) I planning of the work
_	All a second feedbar	V. N.	
1	All support for the	X_None	
	present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this		
	item.		
		Time frame: past	36 months
2	Grants or contracts from	XNone	
	any entity (if not indicated		
	in item #1 above).		
3	Royalties or licenses	XNone	

4	Consulting fees	XNone
5	Payment or honoraria for	XNone
	lectures, presentations, speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert testimony	XNone
7	Support for attending	XNone
	meetings and/or travel	
8	Patents planned, issued	X None
	or pending	
9	Participation on a Data	X None
	Safety Monitoring Board	
	or Advisory Board	
10	Leadership or fiduciary	X None
	role in other board,	
	society, committee or	
	advocacy group, paid or	
	unpaid	
11	Stock or stock options	XNone
12	Receipt of equipment,	X_None
	materials, drugs, medical writing, gifts or other	
	services	
13	Other financial or non- financial interests	X_None
Plea	se summarize the above	e conflict of interest in the following box:
No	one.	
1		
Plea	se place an "X" next to t	the following statement to indicate your agreement:
	-	- · · · · · · · · · · · · · · · · · · ·

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.